ADRA1A
ENSG00000120907
Target class
GPCR
Chromosome
8
Approved drugs
39
Clinical candidates (approved and in development)
46
- Approved drugs
- 39
- Clinical candidates (approved and in development)
- 46
- Chemical probe available
- Yes
- Other names
- ADRA1L1
- Target name
- ADRA1A
- Gene name
- Adrenoceptor alpha 1A
- Gene symbol
- ADRA1A
- Previous gene symbols
- ADRA1C
- Protein name
- Alpha-1A adrenergic receptor (Alpha-1A adrenoreceptor) (Alpha-1A adrenoceptor) (Alpha-1C adrenergic receptor) (Alpha-adrenergic receptor 1c)
- Gene biotype
- Protein coding
- Gene family
- Adrenoceptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 13
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 14.14
- Tissue specificity (Gini)
- 0.631
- Tissue specificity (tau)
- 0.948
- KEGG gene identifiers
- hsa:148
- Protein interaction confidence
- 0.856333
- Protein interaction partners
- 12
- R-HSA-390696
- R-HSA-416476
- R-HSA-416482
- End position
- 26867278
- Start position
- 26748150
- Chromosome
- 8
- Strand
- Reverse
- Nucleus membrane
- Multi-pass membrane protein. Cell membrane
- Multi-pass membrane protein . Cytoplasm . Membrane, caveola . Note=Location at the nuclear membrane facilitates heterooligomerization and regulates ERK-mediated signaling in cardiac myocytes (PubMed:18802028, PubMed:22120526). Colocalizes with GNAQ, PLCB1 as well as LAP2 at the nuclear membrane of cardiac myocytes (PubMed:18802028, PubMed:22120526). Colocalizes with CAVIN4 and CAV3 at the plasma membrane and partly within the cytoplasm in cardiomyocytes (PubMed:24567387). .
- Cytosol
- PubMed 18802028
- PubMed 22120526
- PubMed 24567387
- Tissue specificity (tau)
- 0.947786
- Expression inequality (Gini)
- 0.631079
Expression in transcripts per million
- Liver
- 14.14
- Lung
- 3.75
- Spleen
- 3.27
- Adipose - Visceral (Omentum)
- 2.27
- Heart - Left Ventricle
- 2.27
Expression in transcripts per million
- Liver14.14
- Lung3.75
- Spleen3.27
- Adipose - Visceral (Omentum)2.27
- Heart - Left Ventricle2.27
- Prostate2.23
- Adipose - Subcutaneous2.04
- Breast - Mammary Tissue1.65
- Brain - Cerebellum1.34
- Artery - Tibial1.2
- Colon - Sigmoid1.19
- Brain - Anterior cingulate cortex (BA24)1.18
- Brain - Cortex1.07
- Brain - Frontal Cortex (BA9)0.98
- Testis0.95
- Small Intestine - Terminal Ileum0.88
- Esophagus - Gastroesophageal Junction0.82
- Uterus0.79
- Brain - Amygdala0.77
- Brain - Hippocampus0.73
- Brain - Hypothalamus0.69
- Brain - Caudate (basal ganglia)0.58
- Cervix - Endocervix0.58
- Colon - Transverse0.57
- Minor Salivary Gland0.56
And 29 more, listed on the interactive page.
- GO:0006915
- GO:0006939
- GO:0007165
- GO:0007186
- GO:0007200
- GO:0007267
- GO:0008285
- GO:0010613
- GO:0035556
- GO:0043410
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0031965
- GO:0004937
- GO:0005515
- GO:0046982
increased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood pressure
Biological samples
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac arrhythmia
Biological samples
- cardiovascular
PubMed 28216264smooth-muscle contraction (prostate in particular, effects on the lower urinary tract)
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: smooth-muscle contraction (prostate in particular, effects on the lower urinary tract)
- cardiovascular system
- gastrointestinal
Evidence sourcedizziness
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dizziness
Biological samples
- cardiovascular
PubMed 28216264orthostatic hypotension
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: orthostatic hypotension
Biological samples
- cardiovascular
PubMed 28216264chronic heart failure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: chronic heart failure
Biological samples
- cardiovascular
PubMed 28216264arrhythmia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: arrhythmia
- cardiovascular system
- gastrointestinal
Evidence sourceincreased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased cardiac contractility
Biological samples
- cardiovascular
PubMed 28216264cardiac positive ionotropy
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cardiac positive ionotropy
- cardiovascular system
- gastrointestinal
Evidence sourcevascular hypertrophy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: vascular hypertrophy
Biological samples
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased blood pressure
Biological samples
- cardiovascular
PubMed 28216264orthostatic hypotension
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: orthostatic hypotension
- cardiovascular system
- gastrointestinal
Evidence sourcesexual function
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: sexual function
- cardiovascular system
- gastrointestinal
Evidence sourceblood pressure events
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: blood pressure events
- cardiovascular system
- gastrointestinal
Evidence sourceincreased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pupil diameter
Biological samples
- cardiovascular
PubMed 28216264retrograde ejaculation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: retrograde ejaculation
Biological samples
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased heart rate
Biological samples
- cardiovascular
PubMed 28216264
orthostatic hypotension
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: orthostatic hypotension
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038impact on various aspects of sexual function
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: impact on various aspects of sexual function
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038smooth muscle contraction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: smooth muscle contraction
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038mydriasis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: mydriasis
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038decreased smooth muscle tone
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased smooth muscle tone
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038increased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased blood pressure
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038dizziness
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dizziness
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038decreased insulin release
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased insulin release
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038potential for arrhythmia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: potential for arrhythmia
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038cardiac positive ionotropy
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: cardiac positive ionotropy
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038increased heart rate
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased heart rate
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038
Related records
Trials (1,641)
- : Pulpal Blood Flow With the Use of Intra-nasal Anesthetic
- : Vascular Function in Health and Disease
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- "The Effect Of Subcutaneous Epinephrine Dosage On Blood Loss In Surgical Incision"
- "The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"
- "The Evaluation of Stimulant Withdrawal"
- 10 Vs.15 mcg Norepinephrine Bolus in Severe Maternal Hypotension During Cesarean Delivery
- 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides
- 4% Articaine and 2% Lidocaine by Intraligamentary Technique in Irreversible Pulpitis
- 5 Versus 10 mcg Norepinephrine Bolus in Treatment of Postinduction and Early Intraoperative Hypotension in Emergency Abdominal Surgery
- 7% Hypertonic Saline for Acute Bronchiolitis
- A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
- A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
- A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate
- A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
- A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
- A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip and Knee Arthroplasty
- A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions
- A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions
Drugs (74)
- Alfuzosin Adrenergic receptor alpha-1 agonist
- Alfuzosin hydrochloride Adrenergic receptor alpha-1 agonist
- Alseroxylon Adrenergic receptor alpha antagonist
- Aviptadil Adrenergic receptor alpha antagonist
- Bucindolol Adrenergic receptor alpha-1 antagonist
- Bucindolol hydrochloride Adrenergic receptor alpha-1 antagonist
- Bunazosin Adrenergic receptor alpha-1 antagonist
- Carvedilol Adrenergic receptor alpha-1 antagonist
- Carvedilol phosphate Adrenergic receptor alpha-1 antagonist
- Dabuzalgron Alpha-1a adrenergic receptor partial agonist
- Dapiprazole Alpha-1a adrenergic receptor antagonist
- Dapiprazole hydrochloride Alpha-1a adrenergic receptor antagonist
- Dipivefrin Adrenergic receptor agonist
- Dipivefrin hydrochloride Adrenergic receptor agonist
- Doxazosin Adrenergic receptor alpha-1 antagonist
- Doxazosin mesylate Adrenergic receptor alpha-1 antagonist
- Droxidopa Adrenergic receptor agonist
- Ephedrine Adrenergic receptor agonist
- Ephedrine hydrochloride Adrenergic receptor agonist
- Ephedrine sulfate Adrenergic receptor agonist